| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.denischemlab.com | |
| Market Cap | 119.96 Cr. | |
| Enterprise Value(EV) | 110.04 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 5.33 | Trailing Twelve Months Ending 2022-09 |
| Price-Earning Ratio (PE) | 16.21 | Trailing Twelve Months Ending 2022-09 |
| Industry PE | 32.78 | Trailing Twelve Months Ending 2022-09 |
| Book Value / Share | 51.69 | Trailing Twelve Months Ending 2022-09 |
| Price to Book Value | 1.67 | Calculated using Price: 86.45 |
| Dividend Yield | 1.74 | Period Ending 2022-03 |
| No. of Shares Subscribed | 1.39 Cr. | 13,876,668 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| The company is engaged in the business of manufacturing of Pharmaceuticals Transfusion Solution in Bottles. It offers wide range of sterile intravenous injectables for human and veterinary consumption. The company's product offerings comprise of various products sold across several states in India. It also exports sterile intravenous medicines to countries like Sri Lanka, Nepal, Combodia, Vietnam, Somalia, Ivory Cost etc. In addition to manufacturing its own products which it sells under its own brands, it does manufacture products on contract basis for third parties including certain multinational pharmaceutical companies who market such products under their own brands. | ||
| 1 Day |
|
+1.11% |
| 1 Week |
|
-6.54% |
| 1 Month |
|
-15.12% |
| 3 Month |
|
+11.19% |
| 6 Month |
|
+27.98% |
| 1 Year |
|
+24.03% |
| 2 Year |
|
+121.67% |
| 5 Year |
|
-8.62% |
| 10 Year |
|
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 14.13 | 0.62 | -30.41 | 5.86 | 5.37 | 11.94 | 7.29 | 3.76 | 9.79 | |
| Return on Capital Employed (%) | 15.80 | 10.93 | 5.30 | 12.19 | 9.37 | 11.90 | 11.34 | 6.50 | 13.79 | |
| Return on Assets (%) | 2.87 | 0.12 | -5.36 | 1.38 | 2.20 | 6.15 | 4.15 | 2.39 | 6.64 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 9 | 17 | 16 | 30 | 50 | 56 | 59 | 62 | 66 | 72 | |
| Non Curr. Liab. | 18 | 25 | 22 | 20 | 11 | 6 | 4 | 6 | 5 | 4 | |
| Curr. Liab. | 25 | 39 | 46 | 44 | 40 | 43 | 34 | 25 | 25 | 26 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 52 | 81 | 85 | 94 | 101 | 106 | 97 | 92 | 96 | 102 | |
| Non Curr. Assets | 19 | 44 | 51 | 46 | 48 | 51 | 47 | 44 | 43 | 41 | |
| Curr. Assets | 33 | 37 | 34 | 48 | 53 | 54 | 50 | 49 | 53 | 61 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 52 | 81 | 85 | 94 | 101 | 106 | 97 | 92 | 96 | 102 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
| Net Sales | 67 | 77 | 100 | 113 | 107 | 124 | 136 | 109 | 137 | 155 | |
| Other Income | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 1 | |
| Total Income | 68 | 77 | 100 | 114 | 108 | 126 | 136 | 110 | 138 | 157 | |
| Total Expenditure | -61 | -68 | -91 | -99 | -95 | -110 | -121 | -99 | -122 | -140 | |
| PBIDT | 6 | 10 | 9 | 15 | 13 | 16 | 15 | 11 | 15 | 17 | |
| Interest | -3 | -5 | -7 | -6 | -5 | -3 | -3 | -2 | -1 | -1 | |
| Depreciation | -1 | -4 | -6 | -7 | -6 | -6 | -7 | -6 | -6 | -6 | |
| Taxation | -1 | 0 | -1 | -1 | 0 | 0 | -2 | -1 | -3 | -3 | |
| Exceptional Items | |||||||||||
| PAT | 1 | 0 | -4 | 1 | 2 | 6 | 4 | 2 | 6 | 7 | |
| Adjusted EPS | 4 | 0 | -5 | 1 | 2 | 5 | 3 | 2 | 5 | 5 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | -1 | -2 | 14 | 21 | 7 | 11 | 8 | 13 | 8 | 17 | |
| Cash Fr. Inv. | -1 | -9 | -28 | -13 | -1 | -16 | -2 | -2 | -1 | -10 | |
| Cash Fr. Finan. | 4 | 12 | 13 | -7 | 0 | 1 | -5 | -14 | -6 | -7 | |
| Net Change | 1 | 0 | -1 | 1 | 5 | -4 | 1 | -3 | 1 | 0 | |
| Cash & Cash Eqvt | 2 | 3 | 2 | 3 | 6 | 2 | 3 | 0 | 2 | 1 |
|
Tue, 10 Jan 2023
Reply To Clarification On Price Movement we would like to clarify as under:All the material information that have a bearing on the operation/ performance of the Company which include all price sensitive information under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ("Listing Regulations") have always been disclosed by the Company within the stipulated time. Further there is no pending information or announcement from the Company which may have a bearing on the price behaviour in the scrip.The Company shall continue to make applicable disclosures within the stipulated time. Therefore the movement in the share price of the company is purely due to market conditions and absolutely market driven and the management of the company is in no way connected with any such movement in price.You are requested to take the same on record. |
|
Mon, 09 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 we are hereby submit the certificate issued by Link Intime India Private Limited Registrar and Share Transfer Agent of the Company for the Quarter ended on 31st December 2022. |
|
Mon, 02 Jan 2023
Clarification sought from Denis Chem Lab Ltd The Exchange has sought clarification from Denis Chem Lab Ltd on January 2 2023 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded. The reply is awaited. |
| Mon, 30 Jan 2023 |
Opening at High
|
High Decrease in 1 Month
|
High Increase in 3 Months
|
High Increase in 6 Months
|
High Increase in 2 Years
|
Equities
M.F.
Sectors